Association between adcy9 gene polymorphisms and ritodrine treatment outcomes in patients with preterm labor

Nari Lee; Ha Young Yoon; Jin Young Park; Young Ju Kim; Han Sung Hwang; Jeong Yee; Hye Sun Gwak

doi:10.3390/pharmaceutics13101653

Association between adcy9 gene polymorphisms and ritodrine treatment outcomes in patients with preterm labor

Nari Lee, Ha Young Yoon, Jin Young Park, Young Ju Kim, Han Sung Hwang, Jeong Yee, Hye Sun Gwak

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The purpose of this study was to investigate the genetic effects of ADCY9 on ritodrine responses in patients with preterm labor. Five single nucleotide polymorphisms (SNPs) of the ADYC9 gene in 163 patients in preterm labor were genotyped: rs879619, rs2601796, rs2531988, rs2531995, and rs2230739. Additionally, rs598961 of the PDE4B gene and rs1042719 of the ADRB2 gene were included for analysis. Patients with CC genotype of ADCY9 rs879619 had a 2.0-fold (95% confidence interval [CI]: 1.3, 3.2) higher hazard of time to delivery than T allele carriers. Patients with combined genotypes of CC in ADCY9 rs879619, AA in PDE4B rs598961, and GC, CC in ADRB2 rs1042719 showed a greater hazard of time to delivery than patients with other combinations (adjusted hazard ratio [AHR] 3.2; 95% CI: 1.7, 6.3), whereas patients carrying the C allele of ADCY9 rs2531995, G allele of PDE4B rs598961, and GG genotype of ADRB2 rs1042719 had a lower hazard of time to delivery than patients carrying other genotypes (AHR 0.4; 95% CI: 0.2, 0.7). Regarding ritodrine-induced adverse drug events (ADEs), height less than 160 cm and CC genotype of ADCY9 rs2531995 showed a greater risk of ADEs. The results of our study suggest that ADCY9 polymorphisms could affect the efficacy and safety of β₂-adrenergic agonists.

Original language	English
Article number	1653
Journal	Pharmaceutics
Volume	13
Issue number	10
DOIs	https://doi.org/10.3390/pharmaceutics13101653
State	Published - Oct 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

Adenylyl cyclase 9 gene
Adverse drug events
Preterm labor
Ritodrine
Single nucleotide polymorphism
Time to delivery

Access to Document

10.3390/pharmaceutics13101653

Cite this

@article{c39d3df8d1d0496b8c24ef08286df387,

title = "Association between adcy9 gene polymorphisms and ritodrine treatment outcomes in patients with preterm labor",

abstract = "The purpose of this study was to investigate the genetic effects of ADCY9 on ritodrine responses in patients with preterm labor. Five single nucleotide polymorphisms (SNPs) of the ADYC9 gene in 163 patients in preterm labor were genotyped: rs879619, rs2601796, rs2531988, rs2531995, and rs2230739. Additionally, rs598961 of the PDE4B gene and rs1042719 of the ADRB2 gene were included for analysis. Patients with CC genotype of ADCY9 rs879619 had a 2.0-fold (95% confidence interval [CI]: 1.3, 3.2) higher hazard of time to delivery than T allele carriers. Patients with combined genotypes of CC in ADCY9 rs879619, AA in PDE4B rs598961, and GC, CC in ADRB2 rs1042719 showed a greater hazard of time to delivery than patients with other combinations (adjusted hazard ratio [AHR] 3.2; 95% CI: 1.7, 6.3), whereas patients carrying the C allele of ADCY9 rs2531995, G allele of PDE4B rs598961, and GG genotype of ADRB2 rs1042719 had a lower hazard of time to delivery than patients carrying other genotypes (AHR 0.4; 95% CI: 0.2, 0.7). Regarding ritodrine-induced adverse drug events (ADEs), height less than 160 cm and CC genotype of ADCY9 rs2531995 showed a greater risk of ADEs. The results of our study suggest that ADCY9 polymorphisms could affect the efficacy and safety of β2-adrenergic agonists.",

keywords = "Adenylyl cyclase 9 gene, Adverse drug events, Preterm labor, Ritodrine, Single nucleotide polymorphism, Time to delivery",

author = "Nari Lee and Yoon, {Ha Young} and Park, {Jin Young} and Kim, {Young Ju} and Hwang, {Han Sung} and Jeong Yee and Gwak, {Hye Sun}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = oct,

doi = "10.3390/pharmaceutics13101653",

language = "English",

volume = "13",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "10",

}

TY - JOUR

T1 - Association between adcy9 gene polymorphisms and ritodrine treatment outcomes in patients with preterm labor

AU - Lee, Nari

AU - Yoon, Ha Young

AU - Park, Jin Young

AU - Kim, Young Ju

AU - Hwang, Han Sung

AU - Yee, Jeong

AU - Gwak, Hye Sun

PY - 2021/10

Y1 - 2021/10

N2 - The purpose of this study was to investigate the genetic effects of ADCY9 on ritodrine responses in patients with preterm labor. Five single nucleotide polymorphisms (SNPs) of the ADYC9 gene in 163 patients in preterm labor were genotyped: rs879619, rs2601796, rs2531988, rs2531995, and rs2230739. Additionally, rs598961 of the PDE4B gene and rs1042719 of the ADRB2 gene were included for analysis. Patients with CC genotype of ADCY9 rs879619 had a 2.0-fold (95% confidence interval [CI]: 1.3, 3.2) higher hazard of time to delivery than T allele carriers. Patients with combined genotypes of CC in ADCY9 rs879619, AA in PDE4B rs598961, and GC, CC in ADRB2 rs1042719 showed a greater hazard of time to delivery than patients with other combinations (adjusted hazard ratio [AHR] 3.2; 95% CI: 1.7, 6.3), whereas patients carrying the C allele of ADCY9 rs2531995, G allele of PDE4B rs598961, and GG genotype of ADRB2 rs1042719 had a lower hazard of time to delivery than patients carrying other genotypes (AHR 0.4; 95% CI: 0.2, 0.7). Regarding ritodrine-induced adverse drug events (ADEs), height less than 160 cm and CC genotype of ADCY9 rs2531995 showed a greater risk of ADEs. The results of our study suggest that ADCY9 polymorphisms could affect the efficacy and safety of β2-adrenergic agonists.

AB - The purpose of this study was to investigate the genetic effects of ADCY9 on ritodrine responses in patients with preterm labor. Five single nucleotide polymorphisms (SNPs) of the ADYC9 gene in 163 patients in preterm labor were genotyped: rs879619, rs2601796, rs2531988, rs2531995, and rs2230739. Additionally, rs598961 of the PDE4B gene and rs1042719 of the ADRB2 gene were included for analysis. Patients with CC genotype of ADCY9 rs879619 had a 2.0-fold (95% confidence interval [CI]: 1.3, 3.2) higher hazard of time to delivery than T allele carriers. Patients with combined genotypes of CC in ADCY9 rs879619, AA in PDE4B rs598961, and GC, CC in ADRB2 rs1042719 showed a greater hazard of time to delivery than patients with other combinations (adjusted hazard ratio [AHR] 3.2; 95% CI: 1.7, 6.3), whereas patients carrying the C allele of ADCY9 rs2531995, G allele of PDE4B rs598961, and GG genotype of ADRB2 rs1042719 had a lower hazard of time to delivery than patients carrying other genotypes (AHR 0.4; 95% CI: 0.2, 0.7). Regarding ritodrine-induced adverse drug events (ADEs), height less than 160 cm and CC genotype of ADCY9 rs2531995 showed a greater risk of ADEs. The results of our study suggest that ADCY9 polymorphisms could affect the efficacy and safety of β2-adrenergic agonists.

KW - Adenylyl cyclase 9 gene

KW - Adverse drug events

KW - Preterm labor

KW - Ritodrine

KW - Single nucleotide polymorphism

KW - Time to delivery

UR - http://www.scopus.com/inward/record.url?scp=85117460391&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics13101653

DO - 10.3390/pharmaceutics13101653

M3 - Article

AN - SCOPUS:85117460391

SN - 1999-4923

VL - 13

JO - Pharmaceutics

JF - Pharmaceutics

IS - 10

M1 - 1653

ER -

Association between adcy9 gene polymorphisms and ritodrine treatment outcomes in patients with preterm labor

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this